In 2004 we reported that only 33.2% of older patients eligible for the prescription of an ACE-I under the HOPE criteria were actually receiving one. 5 With more studies showing the beneficial effect of ACE-I and ARBs, prescription practices may have changed since our first survey. We therefore conducted a case note survey of 473 patients attending the Medicine for the Elderly services in Dundee, Scotland, from November 2004 to May 2005 to examine current prescription practice of ACE-I and ARBs in patients with the HOPE criteria. Pearsons chi-squared for discrete variables Table 2 .
On univariate analysis, factors significantly associated with a lower prescription of ACE-I and ARBs were increasing age, lower Mini-Mental State Examination (MMSE) score, physical dependence in basic activities of daily living and living in a nursing home, whereas a previous myocardial infarction had the opposite effect. The above factors were included in a binary logistic regression analysis, using stepwise backwards exclusion at a significance threshold of p=0.05. Age, MMSE and living in a nursing home remained in the model as independent predictors of patients with HOPE criteria not being prescribed an ACE-I or ARB, while a previous myocardial infarction was an independent predictor of patients with HOPE criteria actually receiving one of these agents.
Together, these factors were able to correctly classify 72.1% of patients as being prescribed ACE-Is or ARBs.
While the prescription of ACE-Is and ARBs has risen in older people since our last survey, over 40% of those eligible still do not receive these agents. This may simply reflect that, in older people, therapies are chosen according to the patient's individual circumstances. Further research is needed to elucidate factors influencing prescription of these agents in older people. 
